FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

The FDA approved a supplemental NDA for Reyataz (atazanavir) from E.R. Squibb & Sons, L.L.C., authorizing changes requested in the supplemental application.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• REYATAZ (atazanavir)

Snippet

SUPPL AP for REYATAZ (ATAZANAVIR)